3,011 Danaher Corporation $DHR Shares Sold by River Street Advisors LLC

River Street Advisors LLC reduced its stake in shares of Danaher Corporation (NYSE:DHR) by 75.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 960 shares of the conglomerate’s stock after selling 3,011 shares during the period. River Street Advisors LLC’s holdings in Danaher were worth $213,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Danaher in the second quarter valued at about $10,492,520,000. Jupiter Topco LLC purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $1,456,317,000. Generation Investment Management LLP acquired a new stake in shares of Danaher in the 2nd quarter worth approximately $1,287,949,000. Bank of America Corp DE purchased a new position in Danaher in the 2nd quarter valued at approximately $993,846,000. Finally, Legal & General Group Plc acquired a new position in Danaher during the second quarter worth $801,056,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Up 0.3%

NYSE:DHR traded up $0.61 during trading hours on Friday, reaching $230.36. 3,935,897 shares of the company were exchanged, compared to its average volume of 4,912,513. The firm has a market cap of $161.94 billion, a price-to-earnings ratio of 37.70, a PEG ratio of 2.87 and a beta of 0.76. The stock has a 50 day simple moving average of $216.32 and a 200 day simple moving average of $197.35. Danaher Corporation has a 52-week low of $160.93 and a 52-week high of $242.80. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.63 and a quick ratio of 1.25.

Danaher (NYSE:DHR) last released its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, topping analysts’ consensus estimates of $1.92 by $0.19. Danaher had a return on equity of 11.17% and a net margin of 16.91%. The business had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. During the same period in the prior year, the firm posted $1.89 EPS. The business’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, analysts predict that Danaher Corporation will post 8.59 EPS for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is currently 26.19%.

Key Headlines Impacting Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Barclays increased their price objective on shares of Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Thursday. UBS Group restated a “buy” rating and set a $260.00 target price on shares of Danaher in a research report on Thursday. Wells Fargo & Company lowered their target price on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research note on Sunday, October 18th. Finally, Robert W. Baird lifted their price objective on Danaher from $246.00 to $254.00 and gave the company an “outperform” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.